{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:29:04Z","timestamp":1786998544481,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T00:00:00Z","timestamp":1498521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002293","name":"Department of Industry and Science, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003550","name":"Queensland Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008716","name":"Science and Industry Endowment Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["LP160100633"],"award-info":[{"award-number":["LP160100633"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010424","name":"College of Science, Technology, Engineering, and Mathematics, Youngstown State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010424","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ymthe.2017.06.017","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T17:30:15Z","timestamp":1500139815000},"page":"2332-2344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology"],"prefix":"10.1016","volume":"25","author":[{"given":"Preethi","family":"Eldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara H.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Prow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrilyn R.","family":"Diener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Howley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Suhrbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Hayball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.06.017_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.ymthe.2017.06.017_bib2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/v7041726","article-title":"The evolution of poxvirus vaccines","volume":"7","author":"S\u00e1nchez-Sampedro","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2017.06.017_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02182-16","volume":"91","author":"Garc\u00eda-Arriaza","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib4","first-page":"219","article-title":"Oral wildlife rabies vaccination field trials in Europe, with recent emphasis on France","volume":"187","author":"Aubert","year":"1994","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S0950268800052535","article-title":"The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur","volume":"116","author":"Pastoret","year":"1996","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.ymthe.2017.06.017_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0378-1119(83)90163-4","article-title":"Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA","volume":"25","author":"Smith","year":"1983","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2017.06.017_bib7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.06.017_bib8","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.06.017_bib9","doi-asserted-by":"crossref","first-page":"19ra12","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass","volume":"2","author":"Alcock","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.06.017_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1542\/peds.55.3.342","article-title":"Smallpox vaccination reactions, prophylaxis, and therapy of complications","volume":"55","author":"Goldstein","year":"1975","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2017.06.017_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01641272","article-title":"Passage history, properties and applicability of the attenuated vaccinia virus strain MVA","volume":"3","author":"Mayr","year":"1975","journal-title":"Infection"},{"key":"10.1016\/j.ymthe.2017.06.017_bib12","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1089\/aid.1992.8.1445","article-title":"Highly attenuated poxvirus vectors","volume":"8","author":"Tartaglia","year":"1992","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.ymthe.2017.06.017_bib13","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib14","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1016\/j.vaccine.2009.05.095","article-title":"Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","volume":"27","author":"Suter","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2017.06.017_bib15","unstructured":"European Medicines Agency. (2013). IMVANEX assessment report. Committee for Medicinal Products for Human Use, 30 May 2013, EMA\/369203\/2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002596\/WC500147898.pdf."},{"key":"10.1016\/j.ymthe.2017.06.017_bib16","first-page":"419","article-title":"The avian EB66(R) cell line, application to vaccines, and therapeutic protein production","volume":"64","author":"Brown","year":"2010","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib17","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.vaccine.2009.05.083","article-title":"New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation","volume":"27","author":"Lohr","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2017.06.017_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0042-6822(92)90467-4","article-title":"Immature viral envelope formation is interrupted at the same stage by lac operator-mediated repression of the vaccinia virus D13L gene and by the drug rifampicin","volume":"187","author":"Zhang","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2017.06.017_bib19","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.3390\/v6103787","article-title":"From crescent to mature virion: vaccinia virus assembly and maturation","volume":"6","author":"Liu","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2017.06.017_bib20","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/JVI.73.6.4536-4542.1999","article-title":"Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression","volume":"73","author":"Holzer","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib21","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1128\/jvi.62.4.1297-1304.1988","article-title":"A cowpox virus gene required for multiplication in Chinese hamster ovary cells","volume":"62","author":"Spehner","year":"1988","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib22","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.biotechadv.2015.10.015","article-title":"The art of CHO cell engineering: a comprehensive retrospect and future perspectives","volume":"33","author":"Fischer","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ymthe.2017.06.017_bib23","first-page":"40","article-title":"Recombinant protein therapeutics from CHO cells\u201420 years and counting","volume":"103","author":"Jayapal","year":"2007","journal-title":"Chem. Eng. Prog."},{"key":"10.1016\/j.ymthe.2017.06.017_bib24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/biot.201400388","article-title":"Designing cell lines for viral vaccine production: where do we stand?","volume":"10","author":"Genzel","year":"2015","journal-title":"Biotechnol. J."},{"issue":"Suppl 5","key":"10.1016\/j.ymthe.2017.06.017_bib25","doi-asserted-by":"crossref","first-page":"S510","DOI":"10.1093\/infdis\/jiw370","article-title":"Chikungunya in the Americas: recommendations and conclusions","volume":"214","author":"Graham","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2017.06.017_bib26","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","article-title":"Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen","volume":"17","author":"Burt","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2017.06.017_bib27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrrheum.2012.64","article-title":"Arthritogenic alphaviruses\u2014an overview","volume":"8","author":"Suhrbier","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib28","doi-asserted-by":"crossref","first-page":"e2137","DOI":"10.1371\/journal.pntd.0002137","article-title":"Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study","volume":"7","author":"Schilte","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ymthe.2017.06.017_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.medmal.2015.05.007","article-title":"French guidelines for the management of chikungunya (acute and persistent presentations). November 2014","volume":"45","author":"Simon","year":"2015","journal-title":"Med. Mal. Infect."},{"key":"10.1016\/j.ymthe.2017.06.017_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/1753-6405.12515","article-title":"Chikungunya virus, risks and responses for Australia","volume":"40","author":"Suhrbier","year":"2016","journal-title":"Aust. N. Z. J. Public Health"},{"key":"10.1016\/j.ymthe.2017.06.017_bib31","author":"Glosser","year":"1980"},{"key":"10.1016\/j.ymthe.2017.06.017_bib32","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0022-2836(64)80066-8","article-title":"The replication and coating of vaccinia DNA","volume":"10","author":"Joklik","year":"1964","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0042-6822(60)90015-5","article-title":"The rate of formation of vaccinia deoxyribonucleic acid and vaccinia virus","volume":"10","author":"Salzman","year":"1960","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2017.06.017_bib34","doi-asserted-by":"crossref","first-page":"7714","DOI":"10.1128\/JVI.00207-06","article-title":"A poxvirus host range protein, CP77, binds to a cellular protein, HMG20A, and regulates its dissociation from the vaccinia virus genome in CHO-K1 cells","volume":"80","author":"Hsiao","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib35","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1099\/0022-1317-82-9-2083","article-title":"Vaccinia virus semaphorin A39R is a 50\u201355\u00a0kDa secreted glycoprotein that affects the outcome of infection in a murine intradermal model","volume":"82","author":"Gardner","year":"2001","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/1743-422X-7-327","article-title":"Functional dissection of the alphavirus capsid protease: sequence requirements for activity","volume":"7","author":"Thomas","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.ymthe.2017.06.017_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/jvi.65.1.147-154.1991","article-title":"Internally located cleavable signal sequences direct the formation of Semliki Forest virus membrane proteins from a polyprotein precursor","volume":"65","author":"Liljestr\u00f6m","year":"1991","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib38","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/JVI.77.5.2981-2989.2003","article-title":"Furin processing and proteolytic activation of Semliki Forest virus","volume":"77","author":"Zhang","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00120216","article-title":"Excision of the piggyBac transposable element in\u00a0vitro is a precise event that is enhanced by the expression of its encoded transposase","volume":"98","author":"Elick","year":"1996","journal-title":"Genetica"},{"key":"10.1016\/j.ymthe.2017.06.017_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1128\/CVI.00280-10","article-title":"Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin","volume":"18","author":"Fisher","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"issue":"Suppl 5","key":"10.1016\/j.ymthe.2017.06.017_bib41","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1093\/infdis\/jiw352","article-title":"Whole-inactivated and virus-like particle vaccine strategies for chikungunya virus","volume":"214","author":"DeZure","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"issue":"Suppl 5","key":"10.1016\/j.ymthe.2017.06.017_bib42","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1093\/infdis\/jiw271","article-title":"Development of vaccines for chikungunya fever","volume":"214","author":"Erasmus","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"issue":"Suppl 5","key":"10.1016\/j.ymthe.2017.06.017_bib43","doi-asserted-by":"crossref","first-page":"S500","DOI":"10.1093\/infdis\/jiw369","article-title":"Chikungunya virus vaccines: viral vector-based approaches","volume":"214","author":"Ramsauer","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2017.06.017_bib44","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.4049\/jimmunol.1300304","article-title":"An essential role of antibodies in the control of chikungunya virus infection","volume":"190","author":"Lum","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib45","doi-asserted-by":"crossref","first-page":"e1003312","DOI":"10.1371\/journal.ppat.1003312","article-title":"Development of a highly protective combination monoclonal antibody therapy against chikungunya virus","volume":"9","author":"Pal","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2017.06.017_bib46","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/emmm.201200213","article-title":"Early neutralizing IgG response to chikungunya virus in infected patients targets a dominant linear epitope on the E2\u00a0glycoprotein","volume":"4","author":"Kam","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2017.06.017_bib47","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1128\/JVI.02603-09","article-title":"Chikungunya virus arthritis in adult wild-type mice","volume":"84","author":"Gardner","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib48","doi-asserted-by":"crossref","first-page":"e1006155","DOI":"10.1371\/journal.ppat.1006155","article-title":"RNA-seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation","volume":"13","author":"Wilson","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2017.06.017_bib49","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.4049\/jimmunol.0900255","article-title":"Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response","volume":"184","author":"Hoarau","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib50","doi-asserted-by":"crossref","first-page":"e3354","DOI":"10.1371\/journal.pntd.0003354","article-title":"Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection","volume":"8","author":"Poo","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ymthe.2017.06.017_bib51","first-page":"375","article-title":"[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl)]","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl. Bakteriol. B"},{"key":"10.1016\/j.ymthe.2017.06.017_bib52","doi-asserted-by":"crossref","first-page":"ofv040","DOI":"10.1093\/ofid\/ofv040","article-title":"Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial","volume":"2","author":"Overton","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ymthe.2017.06.017_bib53","doi-asserted-by":"crossref","first-page":"e0138348","DOI":"10.1371\/journal.pone.0138348","article-title":"A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18\u201340 year old subjects with diagnosed atopic dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2017.06.017_bib54","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1128\/JVI.03418-13","article-title":"A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection","volume":"88","author":"Garc\u00eda-Arriaza","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib55","doi-asserted-by":"crossref","first-page":"e2970","DOI":"10.1371\/journal.pntd.0002970","article-title":"A\u00a0novel MVA vectored chikungunya virus vaccine elicits protective immunity in mice","volume":"8","author":"Weger-Lucarelli","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ymthe.2017.06.017_bib56","doi-asserted-by":"crossref","first-page":"e1003756","DOI":"10.1371\/journal.ppat.1003756","article-title":"An increasing danger of zoonotic orthopoxvirus infections","volume":"9","author":"Shchelkunov","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2017.06.017_bib57","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa020534","article-title":"Clinical responses to undiluted and diluted smallpox vaccine","volume":"346","author":"Frey","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.06.017_bib58","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2144\/97236st07","article-title":"Compact, synthetic, vaccinia virus early\/late promoter for protein expression","volume":"23","author":"Chakrabarti","year":"1997","journal-title":"Biotechniques"},{"key":"10.1016\/j.ymthe.2017.06.017_bib59","series-title":"Molecular Virology a Practical Approach","first-page":"257","article-title":"Expression of genes by vaccinia virus vectors","author":"Smith","year":"1993"},{"key":"10.1016\/j.ymthe.2017.06.017_bib60","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/jvi.62.6.1849-1854.1988","article-title":"Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors","volume":"62","author":"Falkner","year":"1988","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0378-1119(88)90424-6","article-title":"A dominant selectable marker for the construction of recombinant poxviruses","volume":"65","author":"Boyle","year":"1988","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2017.06.017_bib62","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/0042-6822(90)90367-Z","article-title":"Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses","volume":"178","author":"Isaacs","year":"1990","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2017.06.017_bib63","series-title":"Vaccinia Virus and Poxvirology Methods and Protocols","first-page":"101","article-title":"Poxviruses and determining virus titer","author":"Kotwal","year":"2004"},{"key":"10.1016\/j.ymthe.2017.06.017_bib64","series-title":"Vaccinia Virus and Poxvirology Methods and Protocols","first-page":"59","article-title":"Easy and efficient protocols for working with recombinant vaccinia virus MVA","author":"Kremer","year":"2012"},{"key":"10.1016\/j.ymthe.2017.06.017_bib65","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1128\/JCM.41.7.3154-3157.2003","article-title":"Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine","volume":"41","author":"Newman","year":"2003","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.ymthe.2017.06.017_bib66","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.vaccine.2011.01.108","article-title":"A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617302800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617302800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:40:45Z","timestamp":1762548045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617302800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1525001617302800"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors.","name":"copyright","label":"Copyright"}]}}